Soluble neuregulin-1 modulates disease pathogenesis in rodent models of Charcot-Marie-Tooth disease 1A

Nature Medicine

Volumn 20, Issue 9, 2014, Pages 1055-1061

  Fledrich, Robert ^a   Stassart, Ruth M ^a,b   Klink, Axel ^a   Rasch, Lennart M ^a   Prukop, Thomas ^a,b   Haag, Lauren ^b   Czesnik, Dirk ^b   Kungl, Theresa ^a   Abdelaal, Tamer A M ^a   Keric, Naureen ^a,c   Stadelmann, Christine ^b   Brück, Wolfgang ^b   Nave, Klaus Armin ^a   Sereda, Michael W ^a,b  

^a MAX PLANCK INSTITUTE OF EXPERIMENTAL MEDICINE   (Germany)

^b UNIVERSITY MEDICAL CENTER GÖTTINGEN   (Germany)

^c JOHANNES GUTENBERG UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; MAMMALIAN TARGET OF RAPAMYCIN; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE KINASE 1; NEU DIFFERENTIATION FACTOR; PERIPHERAL MYELIN PROTEIN 22; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 4,5 BISPHOSPHATE 3 KINASE; PROTEIN KINASE B; NRG1 PROTEIN, RAT;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL DEDIFFERENTIATION; CELL DIFFERENTIATION; CELL SURVIVAL; CHARCOT MARIE TOOTH DISEASE 1A; CONTROLLED STUDY; DEMYELINATION; ENZYME ACTIVATION; ENZYME INHIBITION; HEREDITARY MOTOR SENSORY NEUROPATHY; IMMUNOHISTOCHEMISTRY; INTRACELLULAR SIGNALING; MALE; MOTOR PERFORMANCE; MOUSE; MUSCLE ACTION POTENTIAL; MYELIN SHEATH; MYELINATION; NERVE EXCITABILITY; NERVE FIBER; NERVE INJURY; NEUROFILAMENT; NEUROMUSCULAR SYNAPSE; NONHUMAN; PATHOGENESIS; PERIPHERAL NERVE; PHENOTYPE; POSTNATAL DEVELOPMENT; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; RAT; SCHWANN CELL; SCHWANN CELL CULTURE; SIGNAL TRANSDUCTION; ANIMAL; DISEASE MODEL; METABOLISM; PATHOPHYSIOLOGY; PHYSIOLOGY; TRANSGENIC RAT;

RATTUS; RODENTIA;

ANIMALS; CHARCOT-MARIE-TOOTH DISEASE; DISEASE MODELS, ANIMAL; MALE; NEUREGULIN-1; PHOSPHATIDYLINOSITOL 3-KINASES; PROTO-ONCOGENE PROTEINS C-AKT; RATS; RATS, TRANSGENIC;

EID: 84908336422     PISSN: 10788956     EISSN: 1546170X     Source Type: Journal    
DOI: 10.1038/nm.3664     Document Type: Article

References (45)

1. Sereda, M. et al. A transgenic rat model of Charcot-Marie-Tooth disease. Neuron 16, 1049-1060 (1996).
2. Lupski, J.R. et al. DNA duplication associated with Charcot-Marie-Tooth disease type 1A. Cell 66, 219-232 (1991).
3. Raeymaekers, P. Duplication in chromosome 17p11.2 in Charcot-Marie-Tooth neuropathy type 1a (CMT 1a). Neuromuscul. Disord. 1, 93-97 (1991).
4. Pareyson, D. & Marchesi, C. Diagnosis, natural history, and management of Charcot-Marie-Tooth disease. Lancet Neurol. 8, 654-667 (2009).
5. Fledrich, R., Stassart, R.M. & Sereda, M.W. Murine therapeutic models for Charcot-Marie-Tooth (CMT) disease. Br. Med. Bull. 102, 89-113 (2012).
6. Patzkó, A. & Shy, M.E. Update on Charcot-Marie-Tooth disease. Curr. Neurol. Neurosci. Rep. 11, 78-88 (2011).
7. Berciano, J., Garciá, A., Calleja, J. & Combarros, O. Clinico-electrophysiological correlation of extensor digitorum brevis muscle atrophy in children with Charcot-Marie-Tooth disease 1A duplication. Neuromuscul. Disord. 10, 419-424 (2000).
8. Harding, A.E. & Thomas, P.K. The clinical features of hereditary motor and sensory neuropathy types I and II. Brain 103, 259-280 (1980).
9. Thomas, P.K. et al. The phenotypic manifestations of chromosome 17p11.2 duplication. Brain 120, 465-478 (1997).
10. Burns, J., Ryan, M.M. & Ouvrier, R.A. Evolution of foot and ankle manifestations in children with CMT1A. Muscle Nerve 39, 158-166 (2009).
11. Yiu, E.M., Burns, J., Ryan, M.M. & Ouvrier, R.A. Neurophysiologic abnormalities in children with Charcot-Marie-Tooth disease type 1A. J. Peripher. Nerv. Syst. 13, 236-241 (2008).
12. Fledrich, R. et al. A rat model of Charcot-Marie-Tooth disease 1A recapitulates disease variability and supplies biomarkers of axonal loss in patients. Brain 135, 72-87 (2012).
13. Sereda, M.W., Meyer zu Hörste, G., Suter, U., Uzma, N. & Nave, K.-A. Therapeutic administration of progesterone antagonist in a model of Charcot-Marie-Tooth disease (CMT-1A). Nat. Med. 9, 1533-1537 (2003).
14. Gabreëls-Festen, A.A. et al. Charcot-Marie-Tooth disease type 1A: morphological phenotype of the 17p duplication versus PMP22 point mutations. Acta Neuropathol. 90, 645-649 (1995).
15. Kobsar, I., Hasenpusch-Theil, K., Wessig, C., Müller, H.W. & Martini, R. Evidence for macrophage-mediated myelin disruption in an animal model for Charcot-Marie-Tooth neuropathy type 1A. J. Neurosci. Res. 81, 857-864 (2005).
16. Jessen, K.R. & Mirsky, R. The origin and development of glial cells in peripheral nerves. Nat. Rev. Neurosci. 6, 671-682 (2005).
17. Hanemann, C.O., Gabreëls-Festen, A.A.W.M., Stoll, G. & Müller, H.W. Schwann cell differentiation in Charcot-Marie-Tooth disease type 1A (CMT1A): normal number of myelinating Schwann cells in young CMT1A patients and neural cell adhesion molecule expression in onion bulbs. Acta Neuropathol. 94, 310-315 (1997).
18. Hanemann, C.O., Gabreëls-Fasten, A.A.W.M., Müller, H.W. & Stoll, G. Low affinity NGF receptor expression in CMT1A nerve biopsies of different disease stages. Brain 119, 1461-1469 (1996).
19. Adlkofer, K. et al. Hypermyelination and demyelianting peripheral neuropathy in Pmp22-deficient mice. Nat. Genet. 11, 274-280 (1995).
20. Martini, R., Klein, D. & Groh, J. Similarities between inherited demyelinating neuropathies and Wallerian degeneration: an old repair program may cause myelin and axon perturbation under nonlesion conditions. Am. J. Pathol. 183, 655-660 (2013).
21. Fischer, S., Weishaupt, A., Troppmair, J. & Martini, R. Increase of MCP-1 (CCL2) in myelin mutant Schwann cells is mediated by Mek-Erk signaling pathway. Glia 56, 836-843 (2008).
22. Kohl, B., Fischer, S., Groh, J., Wessig, C. & Martini, R. MCP-1/CCL2 modifies axon properties in a PMP22-overexpressing mouse model for Charcot-Marie-Tooth 1A neuropathy. Am. J. Pathol. 176, 1390-1399 (2010).
23. Napoli, I. et al. A central role for the Erk-signaling pathway in controlling Schwann cell plasticity and peripheral nerve regeneration in vivo. Neuron 73, 729-742 (2012).
24. Mendoza, M.C., Emrah Er, E. & Blenis, J. The Ras-Erk and PI3K-mTOR pathways: cross-talk and compensation. Trends Biochem. Sci. 36, 320-328 (2011).
25. Nobbio, L. et al. Impairment of PMP22 transgenic Schwann cells differentiation in culture: implications for Charcot-Marie-Tooth type 1A disease. Neurobiol. Dis. 16, 263-273 (2004).
26. Syed, N. et al. Soluble neuregulin-1 has bifunctional, concentration-dependent effects on Schwann cell myelination. J. Neurosci. 30, 6122-6131 (2010).
27. Taveggia, C. et al. Neuregulin-1 type III determines the ensheathment fate of axons. Neuron 47, 681-694 (2005).
28. Birchmeier, C. & Nave, K.-A. Neuregulin-1, a key axonal signal that drives Schwann cell growth and differentiation. Glia 56, 1491-1497 (2008).
29. Michailov, G.V. et al. Axonal neuregulin-1 regulates myelin sheath thickness. Science 304, 700-703 (2004).
30. Falls, D.L. Neuregulins and the neuromuscular system: 10 years of answers and questions. J. Neurocytol. 32, 619-647 (2003).
31. Stassart, R.M. et al. A role for Schwann cell-derived neuregulin-1 in remyelination. Nat. Neurosci. 16, 48-54 (2013).
32. Mendes-Ferreira, P., De Keulenaer, G.W., Leite-Moreira, A.F. & Brás-Silva, C. Therapeutic potential of neuregulin-1 in cardiovascular disease. Drug Discov. Today 18, 836-842 (2013).
33. Huxley, C. et al. Correlation between varying levels of PMP22 expression and the degree of demyelination and reduction in nerve conduction velocity in transgenic mice. Hum. Mol. Genet. 7, 449-458 (1998).
34. Bersell, K., Arab, S., Haring, B. & Kühn, B. Neuregulin1/ErbB4 signaling induces cardiomyocyte proliferation and repair of heart injury. Cell 138, 257-270 (2009).
35. Kato, T. et al. Transient exposure of neonatal mice to neuregulin-1 results in hyperdopaminergic states in adulthood: implication in neurodevelopmental hypothesis for schizophrenia. Mol. Psychiatry 16, 307-320 (2011).
36. Haney, C. et al. Ultrastructural distribution of PMP22 in Charcot-Marie-Tooth disease type 1A. J. Neuropathol. Exp. Neurol. 55, 290-299 (1996).
37. Koike, H. et al. Nonmyelinating Schwann cell involvement with well-preserved unmyelinated axons in Charcot-Marie-Tooth disease type 1A. J. Neuropathol. Exp. Neurol. 66, 1027-1036 (2007).
38. Arthur-Farraj, P.J. et al. c-Jun reprograms Schwann cells of injured nerves to generate a repair cell essential for regeneration. Neuron 75, 633-647 (2012).
39. D'Antonio, M. et al. Resetting translational homeostasis restores myelination in Charcot-Marie-Tooth disease type 1B mice. J. Exp. Med. 210, 821-838 (2013).
40. Patzkó, A. et al. Curcumin derivatives promote Schwann cell differentiation and improve neuropathy in R98C CMT1B mice. Brain 135, 3551-3566 (2012).
41. Meyer zu Hörste, G. et al. Antiprogesterone therapy uncouples axonal loss from demyelination in a transgenic rat model of CMT1A neuropathy. Ann. Neurol. 61, 61-72 (2007).
42. Brockes, J.P. et al. Studies on cultured rat Schwann cells. I. Establishment of purified populations from cultures of peripheral nerve. Brain Res. 165, 105-118 (1979).
43. Krishnan, A.V., Lin, C.S.-Y., Park, S.B. & Kiernan, M.C. Axonal ion channels from bench to bedside: a translational neuroscience perspective. Prog. Neurobiol. 89, 288-313 (2009).
44. Nodera, H. et al. Nerve excitability properties in Charcot-Marie-Tooth disease type 1A. Brain 127, 203-211 (2004).
45. Boërio, D., Greensmith, L. & Bostock, H. Excitability properties of motor axons in the maturing mouse. J. Peripher. Nerv. Syst. 14, 45-53 (2009).